Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073879 · ClinicalTrials.gov registry record · NA

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

A NA study of Kidney Cancer, sponsored by Baylor College of Medicine.

Completed
Registry status
NA
Development phase
1
Study location

NCT00073879 is a NA study of Kidney Cancer that has completed, run by Baylor College of Medicine. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073879, a NA study of Kidney Cancer, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells can reject the body's normal tissues. Alemtuzumab and tacrolimus may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining fludarabine and cyclophosphamide with alemtuzumab in treating patients who are undergoing allogeneic stem cell transplantation for recurrent or metastatic renal cell carcinoma (kidney cancer).

Conditions Studied

Interventions

  • DRUG cyclophosphamide
  • DRUG fludarabine phosphate
  • BIOLOGICAL alemtuzumab
  • PROCEDURE allogeneic bone marrow transplantation
  • BIOLOGICAL graft-versus-tumor induction therapy

Study Locations (1)

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Start Date 2003-04
Est. Completion 2004-04
Phase NA

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT00073879

The ClinicalTrials.gov registry entry for NCT00073879 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00073879 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00073879 about?

NCT00073879 is a clinical study titled "Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation". RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted...

What is the current status of trial NCT00073879?

This trial is currently completed. It is a NA study. The study started on 2003-04. Estimated completion is 2004-04.

What conditions does trial NCT00073879 study?

This clinical trial studies the following conditions: Kidney Cancer.

What interventions are being tested in trial NCT00073879?

The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), alemtuzumab (BIOLOGICAL), allogeneic bone marrow transplantation (PROCEDURE), graft-versus-tumor induction therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT00073879?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073879 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.